Edwards Lifesciences (EW) SVP records small open-market stock sale

Rhea-AI Filing Summary

Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported an open-market sale of Common Stock. He sold 567.5266 shares at a price of $86.08 per share and now directly holds 15,334.0948 shares, indicating a relatively small reduction in his position.

Insider Trade Summary

Net Seller: 567.527 shares ($48,853)

Net Sell 1 txn

Insider Dahl Andrew M.

Role SVP, Corporate Controller

Sold 567.527 shs ($49K)

Type	Security	Shares	Price	Value
Sale	Common Stock	567.527	$86.08	$49K

Holdings After Transaction: Common Stock — 15,334.095 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 567.5266 shares Sale price: $86.08 per share Shares after transaction: 15,334.0948 shares +1 more

4 metrics

Shares sold 567.5266 shares Open-market sale of Common Stock

Sale price $86.08 per share Reported transaction price

Shares after transaction 15,334.0948 shares Direct holdings following sale

Number of sale transactions 1 transaction Single non-derivative open-market sale

Key Terms

open-market sale, Common Stock, Form 4

3 terms

open-market sale financial

"The transaction is described as an open-market sale of Common Stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"The reported security title for the transaction is Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"Details of the insider transaction are disclosed in a Form 4 filing."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dahl Andrew M.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Corporate Controller

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		S		567.5266	D	$86.08	15,334.0948	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Edwards Lifesciences (EW) report?

Edwards Lifesciences reported that executive Andrew M. Dahl completed an open-market sale of Common Stock. The Form 4 shows one sale transaction, giving investors transparency into recent insider trading activity by a senior vice president and corporate controller.

How many Edwards Lifesciences (EW) shares did Andrew M. Dahl sell?

Andrew M. Dahl sold 567.5266 shares of Edwards Lifesciences Common Stock. This single transaction modestly reduced his direct ownership while leaving him with a substantially larger remaining stake reported in the same filing after the sale was completed.

At what price were Edwards Lifesciences (EW) shares sold in this Form 4?

The reported sale was executed at $86.08 per share. This reflects the transaction price for the 567.5266 shares of Common Stock sold in the open market as disclosed in the insider trading report filed with regulators.

How many Edwards Lifesciences (EW) shares does Andrew M. Dahl hold after the sale?

Following the reported sale, Andrew M. Dahl directly holds 15,334.0948 Edwards Lifesciences shares. This post-transaction figure, shown in the Form 4, helps investors gauge the scale of the sale relative to his remaining ownership stake.

Was the Edwards Lifesciences (EW) insider transaction an open-market sale?

Yes. The filing labels the transaction as an open-market sale of Common Stock. It uses transaction code “S” with a description indicating a sale in the open market or a private transaction, clarifying that it was not a grant, gift, or tax withholding.